217 related articles for article (PubMed ID: 31232133)
1. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
Ullén A
Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
[No Abstract] [Full Text] [Related]
2. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E; Assi T; Kattan J
Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
[No Abstract] [Full Text] [Related]
3. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
4. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
Necchi A; Giardiello D; Mariani L
Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
[No Abstract] [Full Text] [Related]
5. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
Necchi A; Raggi D; Giannatempo P; Sonpavde G; Galsky MD; Bellmunt J; Mariani L; Miceli R
Clin Genitourin Cancer; 2017 Oct; 15(5):509-512.e9. PubMed ID: 28478885
[No Abstract] [Full Text] [Related]
6. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
Necchi A; Raggi D; Giannatempo P; Alessi A; Serafini G; Colecchia M; Ali SM; Chung JH
Eur J Cancer; 2018 Jun; 96():128-130. PubMed ID: 29680362
[No Abstract] [Full Text] [Related]
7. Making urothelial carcinomas less immune to immunotherapy.
Ramos JD; Yu EY
Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
[TBL] [Abstract][Full Text] [Related]
8. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
9. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
10. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
11. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
Balar AV
Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
[No Abstract] [Full Text] [Related]
12. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
13. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
[TBL] [Abstract][Full Text] [Related]
14. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
16. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
17. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
18. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
Gill DM; Sonpavde G; Pal SK; Agarwal N
Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
[No Abstract] [Full Text] [Related]
19. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
